早期结外NK/T细胞淋巴瘤鼻型同步与非同步放化疗疗效分析

doi:10.3760/cma.j.cn113030-20210922-00368

摘要
图/表
参考文献
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的比较早期结外NK/T细胞淋巴瘤鼻型(NKTCL)同步与非同步放化疗疗效。方法收集2007—2020年贵州医科大学附属肿瘤医院收治的278例早期NK/T细胞淋巴瘤综合治疗患者,按Nomogram改进版风险指数(NRI)预后模型,根据有无任何预后不良因素[年龄>60岁、血清乳酸脱氢酶(LDH)增高、美国东部肿瘤协作组(ECOG)评分≥2分、原发肿瘤侵犯(PTI)、Ann Arbor分期Ⅱ期]分为预后良好组49例,以及含有任何一项预后不良因素的预后不良组229例。其中145例采用同步放化疗,133例采用非同步放化疗。结果全组5年总生存(OS)率为71.0%,无进展生存(PFS)率为67.6%。预后良好组和预后不良组5年OS率分别为95.6%和65.4%(P<0.001)。预后不良组中NRI=1分中低危组、NRI=2分中高危组、NRI≥3分高危组患者各组的5年OS率分别为72.1%、61.1%、47.7%(P=0.007)。同步放化疗组与非同步放化疗组疗效无显著差异,5年OS率分别为70.6%、69.8%(P=0.783)、5年PFS率分别为67.6%、65.2%(P=0.631)。进一步分层分析显示,NRI=1分中低危组患者同步放化疗组与非同步放化疗组5年OS率分别为73.1%、76.5%(P=0.576),NRI=2分中高危组患者分别为62.6%、69.3%(P=0.427),NRI≥3分高危组患者分别为58.1%、42.3%(P=0.954),均无明显差异。结论综合治疗能显著改善预后不良组早期NKTCL的预后,在放化疗的顺序上同步放化疗和非同步放化疗5年OS率、5年PFS率无显著差异。对于预后不良早期NKTCL可以采用耐受性更好的序贯治疗。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘秋琳
	吴涛
	张婧
	胡云飞
	陈梦翔
	黄韵红

关键词 ：结外NK/T细胞淋巴瘤, 鼻型, 同步放化疗, 预后

Abstract：Objective To compare the efficacy of concurrent and asynchronous radiochemotheray for early extranodal nasal natural killer/T-cell lymphoma (NKTCL). Methods From 2007 to 2020, 278 patients with early NKTCL treated with comprehensive treatment in the Affiliated Tumor Hospital of Guizhou Medical University were recruited. According to the adjusted Nomogram-revised risk index (NRI) prognostic model, there were 49 cases in the good prognostic group without adverse prognostic factors (age>60 years old,increased serum lactate dehydrogenase (LDH), ECOG score ≥2, primary tumor invasion (PTI), Ann Arbor stage Ⅱ,and 229 cases in the poor prognostic group with any adverse prognostic factors. 145 of these cases were treated with concurrent radiochemotherapy, and 133 of them were treated with asynchronous radiochemotherapy. Results The 5-year overall survival (OS) rate of the whole group was 71.0%, and the progression-free survival (PFS) rate was 67.6%. The 5-year OS rate in the good prognostic group was 95.6%, and 65.4% in the poor prognostic group (P<0.001). In the poor prognostic group, the 5-year OS rates of patients with NRI=1(low-and moderate-risk group), NRI=2(moderate-and high-risk group), NRI≥3(high-risk group) were 72.1%, 61.1% and 47.7%, respectively (P=0.007). There was no significant difference in curative effect between the concurrent and asynchronous radiochemotherapy groups. The 5-year OS rates were 70.6% and 69.8%(P=0.783), and the 5-year PFS rates were 67.6% and 65.2%(P=0.631). Further stratified analysis showed that the 5-year OS rates of patients with NRI=1 receiving concurrent and asynchronous radiochemotherapy were 73.1% and 76.5%(P=0.576),62.6% and 69.3%(P=0.427) for those with NRI=2, and 58.1% and 42.3% for those with NRI≥3(P=0.954). Conclusions Comprehensive treatment can significantly improve the prognosis of early NKTCL in the poor prognostic group. In the sequence of radiotherapy and chemotherapy, there is no significant difference in 5-year OS and PFS rates between concurrent and asynchronous radiochemotherapy. Sequential treatment with better tolerance can be adopted for early NKTCL with poor prognosis.

Key words： Extranodal Natural killer/T-cell lymphoma, nasal type Concurrent chemo-radiotherapy Prognosis

收稿日期: 2021-09-22

通讯作者: 吴涛,Email:wutao03417@sina.com

引用本文:

刘秋琳,吴涛,张婧等. 早期结外NK/T细胞淋巴瘤鼻型同步与非同步放化疗疗效分析[J]. 中华放射肿瘤学杂志, 2022, 31(6): 532-538.

Liu Qiulin,Wu Tao,Zhang Jing et al. Analysis of treatment results of concurrent and asynchronous radiochemotherapy for early extranodal NK/T cell lymphoma[J]. Chinese Journal of Radiation Oncology, 2022, 31(6): 532-538.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20210922-00368 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I6/532

[1] Kim TM, Lee SY, Jeon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type:a national survey of the korean cancer study group[J]. Ann Oncol, 2008, 19(8):1477-1484. DOI:10.1093/annonc/mdn147.
[2] Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage Ⅰ e and ⅡE nasal natural killer/t-cell lymphoma[J]. J Clin Oncol, 2006, 24(1):181-189. DOI:10.1200/JCO.2005.03.2573.
[3] Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of waldeyer ring[J]. Blood, 2008, 112(8):3057-3064. DOI:10.1182/blood-2008-05-160176.
[4] Vazquez A, Khan MN, Blake DM, et al. Extranodal natural killer/t-cell lymphoma:A population-based comparison of sinonasal and extranasal disease[J]. Laryngoscope, 2014, 124(4):888-895. DOI:10.1002/lary.24371.
[5] Lee J, Suh C, Park YH, et al. Extranodal natural killer t-cell lymphoma, nasal-type:a prognostic model from a retrospective multicenter study[J]. J Clin Oncol, 2006, 24(4):612-618. DOI:10.1200/JCO.2005.04.1384.
[6] Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/t-cell lymphoma:a study of 136 cases from the international peripheral t-cell lymphoma project[J]. Blood, 2009, 113(17):3931-3937. DOI:10.1182/blood-2008-10-185256.
[7] Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms:aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type[J]. Ann Oncol, 2010, 21(5):1032-1040. DOI:10.1093/annonc/mdp418.
[8] Vazquez A, Khan MN, Blake DM, et al. Extranodal natural killer/t-cell lymphoma:A population-based comparison of sinonasal and extranasal disease[J]. Laryngoscope, 2014, 124(4):888-895. DOI:10.1002/lary.24371.
[9] Lee J, Suh C, Park YH, et al. Extranodal natural killer t-cell lymphoma, nasal-type:a prognostic model from a retrospective multicenter study[J]. J Clin Oncol, 2006, 24(4):612-618. DOI:10.1200/JCO.2005.04.1384.
[10] Lu NN, Li YX, Wang WH, et al. Clinical behavior and treatment outcome of primary nasal diffuse large b-cell lymphoma[J]. Cancer, 2012, 118(6):1593-1598. DOI:10.1002/cncr.26452.
[11] Li YX, Liu QF, Wang WH, et al. Failure patterns and clinical implications in early stage nasal natural killer/t-cell lymphoma treated with primary radiotherapy[J]. Cancer, 2011, 117(22):5203-5211. DOI:10.1002/cncr.26167.
[12] Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than international prognostic index in stage Ⅰ (e)/Ⅱ(e) extranodal NK/T-cell lymphoma, nasal type[J]. Blood, 2005, 106(12):3785-3790. DOI:10.1182/blood-2005-05-2056.
[13] Cheung MM, Chan JK, Lau WH, et al. Early stage nasal NK/T-cell lymphoma:clinical outcome, prognostic factors, and the effect of treatment modality[J]. Int J Radiat Oncol Biol Phys, 2002, 54(1):182-190. DOI:10.1016/s0360-3016(02)02916-4.
[14] Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and waldeyer ring natural killer/t-cell lymphoma[J]. Clin Cancer Res, 2009, 15(8):2905-2912. DOI:10.1158/1078-0432. CCR-08-2914.
[15] Kwong YL, Kim SJ, Tse E, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage Ⅰ/Ⅱ NK/T-cell lymphoma[J]. Ann Oncol, 2018, 29(1):256-263. DOI:10.1093/annonc/mdx684.
[16] Yang Y, Zhang YJ, Zhu Y, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type:a multicenter study[J]. Leukemia, 2015, 29(7):1571-1577. DOI:10.1038/leu.2015.44.
[17] Wang ZY, Li YX, Wang WH, et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents[J]. Blood, 2009, 114(23):4771-4776. DOI:10.1182/blood-2009-07-235853.
[18] Qi SN, Yang Y, Song YQ, et al. First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma:a retrospective analysis from the CLCG[J]. Blood Adv, 2020, 4(13):3141-3153. DOI:10.1182/bloodadvances.2020001852.
[19] 吴涛, 刘秋琳, 胡云飞, 等. 早期结外鼻型NK/T细胞淋巴瘤风险分层治疗的远期效果分析[J]. 中华肿瘤杂志, 2019, 41(11):859-864. DOI:10.3760/cma.j.issn.0253-3766.2019.11.011.
Tao W, Qiulin L, Yunfei H, et al. Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma[J]. Chin J Oncol,2019,41(11):859-864. DOI:10.3760/cma.j.issn.0253-3766.2019.11.011.
[20] Deng XW, Wu JX, Wu T, et al. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma:a multicenter study from the China lymphoma collaborative group (CLCG)[J]. Radiother Oncol, 2018, 129(1):3-9. DOI:10.1016/j.radonc.2018.04.026.
[21] Qi SN, Yang Y, Zhang YJ, et al. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era:a China lymphoma collaborative group study[J]. Am J Hematol, 2020, 95(9):1047-1056. DOI:10.1002/ajh.25878.
[22] Yoon DH, Kim SJ, Jeong SH, et al. Phase Ⅱ trial of concurrent chemoradiotherapy with l-asparaginase and MIDLE chemotherapy for newly diagnosed stage Ⅰ/Ⅱ extranodal NK/T-cell lymphoma, nasal type (CISL-1008)[J]. Oncotarget, 2016, 7(51):85584-85591. DOI:10.18632/oncotarget.11319.
[23] Kwong YL, Kim SJ, Tse E, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage Ⅰ/Ⅱ NK/T-cell lymphoma[J]. Ann Oncol, 2018, 29(1):256-263. DOI:10.1093/annonc/mdx684.
[24] Chen SY, Yang Y, Qi SN, et al:Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era:indication for prognostication and clinical decision-making[J]. Leukemia, 2021, 35(1):130-142. DOI: 10.1038/s41375-020-0791-3.
[25] Jiang L, Gu ZH, Yan ZX, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma[J]. Nat Genet, 2015, 47(9):1061-1066. DOI:10.1038/ng.3358.
[26] Wen H, Ma H, Cai Q, et al. Recurrent ECSIT mutation encoding v140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma[J]. Nat Med, 2018, 24(2):154-164. DOI:10.1038/nm.4456.